A discovery by Queensland scientists could be the key to stopping damage caused by uncontrolled inflammation in a range of common diseases including liver disease, Alzheimer’s and gout.
University of Queensland researchers have uncovered how an inflammation process automatically switches off in healthy cells, and are now investigating ways to stop it manually when it goes awry.
“Now that we understand how this pathway naturally turns off in health, we can investigate why it doesn’t turn off in disease — so it’s very exciting,” Dr Schroder said.
Her work at IMB’s Centre for Inflammation and Disease Research focuses on inflammasomes, which are machine-like protein complexes at the heart of inflammation and disease.
“These complexes form when an infection, injury or other disturbance is detected by the immune system, and they send messages to immune cells to tell them to respond,” Dr Schroder said.
“If the disturbance can’t be cleared, such as in the case of amyloid plaques in Alzheimer’s, these molecular machines continue to fire, resulting in neurodegenerative damage from the sustained inflammation.”
Dr Schroder’s team, led by Dr Dave Boucher, discovered that inflammasomes normally work with an in-built timer switch, to ensure they only fire for a specific length of time once triggered.
“The inflammasome initiates the inflammation process by activating a protein that functions like a pair of scissors, and cuts itself and other proteins,” Dr Schroder said.
“What we’ve found is that after a period of time this protein cuts itself a second time to turn off the pathway, so if we can tweak this system we may be able to turn it off manually in disease.”
Dr Schroder’s laboratory has begun studying the inflammasome in fatty liver disease, a rapidly growing health issue due to the increasing global incidence of obesity and diabetes.
“In some patients with this condition the liver becomes increasingly fatty and inflamed, and this can lead to cirrhosis – which can require liver transplantation – or even liver cancer.”
Compounds to block inflammasome have been developed by IMB researchers including Dr Schroder, and are being commercialised by start-up drug development company Inflazome Ltd.
The research, published in the Journal of Experimental Medicine (DOI: 10.1084/jem.20172222), was supported by the Australian Research Council, and involved laboratories at IMB and the UQ School of Chemistry and Molecular Biosciences.
Imaging for the project was performed in the IMB Cancer Biology Imaging Facility, funded by the Australian Cancer Research Foundation.
Additional video: inflammasome animation on YouTube.
The Latest on: Uncontrolled inflammation
- Additional data from Pluristem’s Phase II IC study were presented at the 2018 American Heart Association Scientific Sessions on November 12, 2018 at 4:30 am
Weiss. “The data we presented at the AHA suggest that PLX-PAD may play a meaningful role in lowering inflammation and maintain better glycemic control reflecting the potential of this non ... […]
- New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation on November 12, 2018 at 3:30 am
Additional analysis of the Phase II IC data confirmed the optimal dosing regimen of PLX-PAD in the treatment of peripheral arterial diseases (PAD) - two administrations of 300 million cells, each orig... […]
- Surgery may be necessary to control inflammatory bowel disease on November 7, 2018 at 1:59 pm
DEAR MAYO CLINIC: A year after colon resection for inflammatory bowel disease, I am still having two or three uncontrollable loose movements a day. I take an anti-diarrhea medication, but it does not ... […]
- Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation on November 6, 2018 at 11:44 am
1 Department of Biochemistry, Duke University, Durham, NC 27710, USA. 2 Department of Medicine, Duke University, Durham, NC 27710, USA. 3 Department of Dermatology, Duke University, Durham, NC 27710, ... […]
- FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis on November 5, 2018 at 11:29 pm
Eye and eyelid inflammation, including redness ... many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ ... […]
- Assam CM blames inflammatory statements by parties, media for Tinsukia killings on November 2, 2018 at 8:49 am
Sonowal held "inflammatory statements" by a section of political parties and the media responsible for the attack that took place on November 1. He appealed to the people to maintain peace and communa... […]
- A new mechanism in the control of inflammation on October 18, 2018 at 11:10 am
Kidney infection with the fungal pathogen Candida albicans causes tissue damage. In wild-type mice, DNGR-1 expressed on dendritic cells detects this injury, and this triggers a reduction in the produc... […]
- Inflammation Not LDL Increases Risks on September 3, 2018 at 12:16 pm
Antioxidants in correct doses, chemical forms, and in correct ratios of one another along with anti-inflammatory agents may help to control inflammation and oxidation. Anti-inflammatory foods include ... […]
- Study: Marijuana can help reduce symptoms of inflammatory bowel diseases on August 13, 2018 at 5:37 pm
“For the first time, we have an understanding of the molecules involved in the process and how endocannabinoids and cannabinoids control inflammation,” said Beth McCormick, vice chair and professor of ... […]
- Cannabis helps control and prevent intestine inflammation in mice, study finds on August 13, 2018 at 1:42 pm
Some marijuana users have reported positive effects from cannabis on intestine inflammation conditions such as ulcerative colitis and Crohn’s disease. Scientists have discovered a biological mechanism ... […]
via Google News and Bing News